Placebo-controlled of oral IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation while receiving QD standard dose PPI

  • Up to 96 hours of pH monitoring with a Bravo during screening (Bravo will be done at Eastside Endoscopy Center)
  • Persistent breakthrough ≥ 4 days per week over the last 8 weeks before screening
  • Epigastric pain or epigastric burning cannot be pre-dominant symptom at screening
  • IW-3718 is sustained release engineered form of colesevelam, a bile acid dequestrant
  • Study drug is 1500mg IW-3718 BID following morning and evening meals